Prevail Therapeutics is a US-based gene therapy company focused on developing treatments for neurodegenerative diseases. Founded in 2017 and headquartered in New York, NY, Prevail was acquired by Eli Lilly and Company in 2021 for approximately $880 million, becoming a wholly-owned subsidiary of Lilly[1].
Prevail's mission is to develop gene therapies that address the underlying genetic causes of neurodegenerative disorders, with initial focus on Parkinson's disease patients carrying GBA1 or LRRK2 mutations. Their AAV9-based platform enables delivery of therapeutic genes to the central nervous system[2].
| Attribute | Value |
|---|---|
| Parent Company | Eli Lilly and Company |
| Founded | 2017 |
| Headquarters | New York, NY |
| Status | Subsidiary of Eli Lilly |
| CEO | Gillian H. Mayer (GM, Prevail) |
In December 2021, Eli Lilly announced the acquisition of Prevail Therapeutics for approximately $880 million ($22.50 per share)[3]. This acquisition:
| Round | Year | Amount |
|---|---|---|
| Series A | 2017 | $30 million |
| Series B | 2019 | $75 million |
PR001 is Prevail's lead clinical program, an AAV9 gene therapy for Parkinson's disease patients with GBA1 mutations[4].
The PROVIEW trial is evaluating PR001 in Parkinson's disease patients with GBA1 mutations:
Patient Criteria:
Endpoints:
Status: Enrolling (2024)
PR004 is a preclinical gene therapy program targeting LRRK2-associated Parkinson's disease[5].
Prevail/Lilly's expanded pipeline includes:
Prevail uses AAV9 capsids for CNS gene delivery because:
As part of Lilly, Prevail leverages:
GBA1 mutations are among the most common genetic risk factors for Parkinson's disease:
LRRK2 mutations (particularly G2019S) cause autosomal dominant Parkinson's disease:
| Company | Drug | Mechanism | Phase |
|---|---|---|---|
| uniQure | AAV-GBA | Gene therapy | Phase 1 |
| Passage Bio | PBFT02 | AAVhu68-GBA | Phase 1 |
| Denali/Biogen | DNL151 | LRRK2 inhibitor | Phase 2b |
| Neurocrine | -- | Gene therapy | Discovery |
Alzheimer's Disease — Gene therapy pipeline](/genes/th)